Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeu

Transforming the Treatment of Cancer

and Inflammation Corporate Presentation September 2021 Exhibit 99.1

Legal Disclaimers Statements in this

Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.'s (the "Company," "we," or "us") research and

clinical development plans; current and future drug candidates; business strategy and plans; regulatory pathways; and our ability to complete certain milestones. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "upcoming,"

"milestone," "potential," "target" or the negative of these terms or similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These

forward-looking statements are based on the current beliefs of the Company's management with respect to future events and trends and are subject to known and unknown risks and uncertainties, including those described in the "Risk

Factors" section of our most recent Form 10-Q filed with the Securities and Exchange Commission, and any current and periodic reports filed thereafter, that may cause our actual performance or achievements to be materially different from

any future performance or achievements expressed or implied by the forward-looking statements in this Presentation. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication,

assurance or guarantee that any assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of such assumptions, fully stated in the Presentation. You are cautioned not to place undue reliance on

these forward-looking statements, which speak only as of the date this Presentation is given. Although we believe that the beliefs and assumptions reflected in the forward-looking statements are reasonable, we cannot guarantee future performance or

achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Presentation. This Presentation discusses drug candidates that are under clinical study

and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of any drug candidates for any use for which such drug candidates are being studied.

DISCOVERY Oral Drugs Targeting Critical

Immune Drivers of Disease RPT193 (Inflammation): Oral agent targets inflammatory Th2 cells PoC in Phase 1b achieved in AD: efficacy on all key exploratory endpoints with excellent safety and tolerability FLX475 (Oncology): Selectively targets

immunosuppressive tumor Treg PoC in Phase 2 with monotherapy and combo activity observed HPK1 (Oncology) Other Targets CLINICAL Proprietary discovery engine Diversified pipeline Large market opportunities Multiple near-term clinical

readouts Strategic collaborations

Proprietary Drug Discovery and

Development Engine R Drug discovery Clinical development to POC Rapid Interrogating clinically-relevant big datasets to identify targets and biomarkers Driven by data to improve chances of clinical success Critical immune drivers of cancer and

inflammation A Analytics P Patient selection T Targeting

RPT193: CCR4 Antagonist for

Inflammatory Diseases

RPT193: Oral CCR4 Antagonist for

Inflammatory Diseases RPT193 is a highly potent and selective once-daily oral CCR4 antagonist that targets inflammation more specifically than JAK inhibitors and acts upstream of the injectables Phase 1b trial demonstrated clear benefit in patients

with moderate-to-severe AD, with favorable safety and tolerability No laboratory safety monitoring or black box warning expected Next steps: Phase 2b trial in AD and a Phase 2a trial in asthma Normal Human Skin AD Lesional Skin

RPT193 Targets Th2 Cells: Key Drivers

of Inflammation in Atopic Dermatitis, Asthma, and Other Diseases Epithelial Barrier Surface CCR4 Th2 IL-5 IL-4 IL-13 Inflammation Thickening Itch Signaling via CCR4 regulates Th2 cell migration into inflamed tissues and enhances cytokine secretion

Cytokines Allergen, Microbes RPT193 is a potent and selective oral CCR4 antagonist that specifically inhibits Th2 cell migration, function and activation. CCL17 CCL22 anti-IL4R Ab anti-IL5/R Ab anti-IL13 Ab

Atopic Dermatitis and Asthma Represent

Major Markets Atopic Dermatitis (AD) Common disease affecting ~19M adults and ~10M children in the US $24B projected market by 2029* Asthma Asthma affects ~15M adults and children in the US $21B projected market by 2029* High unmet need: a

well-tolerated, safe and effective, oral drug that does not require laboratory safety monitoring RPT193 has the potential to address this unmet need * Decision Resources Guide; EU, US, and Japan market

Enrolled 31 patients into a

double-blind, randomized trial with 2:1 allocation of RPT193 to placebo Monotherapy study: steroid and immunosuppressant washout period; rescue steroids not permitted through Day 43 Trial was not powered for any specific endpoint Exploratory

endpoints include: EASI, Pruritis Numerical Rating Scale (NRS), and vIGA Data presented are from the Intent to Treat dataset Phase 1b Trial Explored RPT193 Activity in Patients with Moderate-to-Severe Atopic Dermatitis Obtain Informed Consent

12-month history of AD 18-65 years of age (inclusive) BMI 18 and <40 kg/m2 BSA 10% EASI 12 vIGA 3 Screening (Up to 35 days) Day -35 -1 RPT193 400 mg once daily Placebo Randomization (2:1) Treatment (28 days)

Follow-up (14 days) 1 29 8 15 43 Study Assessments (Day 1 to 43)

Phase 1b Baseline Demographics

Placebo RPT193 N 10 21 Age, Mean (Range) 35.8 (22-64) 41.0 (19-63) Female, n (%) 4 (40.0%) 12 (57.1%) Baseline Characteristics EASI, Mean (Range) 21.07 (13.6-45.5) 18.49 (12-30) BSA, Mean (Range) 24.5 (10-61) 23.3 (11-55) vIGA 3, n (%) 8 (80.0%) 18

(85.7%) Peak NRS, Mean (Range) 7.3 (3-10) 6.9 (3-10) Peak NRS 4, n (%) 9 (90.0%) 20 (95.2%)

RPT193 Differentiated from Placebo

for EASI and EASI-50 at Day 29 with Further Improvement at Day 43 % Improvement in EASI Proportion of EASI-50 19.3% 43.6% 32.9% 41.9% Follow-up Treatment Follow-up Treatment *p < 0.05 * *

RPT193 Differentiated from Placebo

for vIGA Clear/Almost Clear at Day 29 with Further Differentiation at Day 43 0.0% 0.0% 4.8% 14.3% Proportion of vIGA 0/1 (Clear/Almost Clear)

RPT193 Demonstrated Clinically

Meaningful Improvement in Itch Compared to Placebo at Day 29 Proportion of NRS-4* 22.2% 45.0% *At least a 4-point improvement among patients with a baseline pruritis NRS 4

Phase 1b Safety No SAEs reported All

AEs reported were mild or moderate in intensity No clinically significant safety laboratory abnormalities observed Overall safety profile to date suggests a well-tolerated oral drug that should not require laboratory safety monitoring

RPT193 6-Week Efficacy Compared

to Other Drugs at 12-16 Weeks* RPT193 RPT193 400 mg Biologics Orals Dupilumab Ph3 (300 mg q2wk) Lebrikizumab Ph2 (250 mg q2wk) Tralokinumab Ph3 (300 mg q2wk) Abrocitinib Ph3 (200 mg) Baricitinib Ph3 (2 mg) Etrasimod Ph2 (2 mg) Upadicitinib

Ph2,3 (15 mg) % EASI improvement EASI-50 vIGA 0 or 1 100 RPT193 RPT193 0 40 20 60 All data shown are placebo-adjusted * Comparisons are based on published data and relative properties of other agents and do not reflect a head-to-head comparative

study or clinical trial

Next Steps for the RPT193 Program

RPT193 Phase 2 Trials Phase 1b Atopic Dermatitis Phase 2b Atopic Dermatitis Phase 2a Asthma PoC Achieved Adults with moderate-to-severe AD 16-week dosing period Multiple dose levels of RPT193 vs. placebo Goal: Evaluate efficacy and safety at 16

weeks and determine optimal dose for Phase 3 trials In planning

RPT193 Program Summary Data from

the Phase 1b study in patients with atopic dermatitis demonstrated clear benefit on all key exploratory clinical endpoints including EASI and vIGA Continued deepening of responses through the 2-week follow-up period suggests higher levels of

efficacy could be achieved in longer studies Profile suggests an effective, well-tolerated oral molecule not needing laboratory safety monitoring, with positioning ahead of injectables and JAK inhibitors Additional late-breaking Phase 1b data to be

presented at EADV Congress Next steps: 16-week Phase 2b study in patients with moderate-to-severe AD and a Phase 2a study in patients with asthma

FLX475: CCR4 Antagonist for

Treg Are Key Targets in the Tumor

Microenvironment (TME) Correlate with poor prognosis across most cancers Mechanism for immune evasion by viruses and tumors Barrier to checkpoint inhibitor efficacy Challenge: selective inhibition of Treg in the TME Depleting antibodies targeting

CD25, CCR4, etc. do not appear to have adequate selectivity Treg CD8 Cancer Types Bruni D et al. Nat Rev Cancer 2020

FLX475: Oral CCR4 Antagonist in

Phase 2 Highly potent and selective CCR4 small molecule antagonist Selectively blocks tumor Treg while sparing normal tissues and beneficial cells Potential for superior safety and efficacy compared to depleting antibodies Issued U.S. composition of

matter patent with coverage through 2037 Monotherapy and combination antitumor activity in charged cancers Blocks interaction with CCR4 ligands CCL22 and CCL17 on Treg

Identification and Characterization

of Charged Tumors "Charged" tumors: high levels of CCR4 ligands, Treg and CD8 T cells Potential for both monotherapy and combination activity Represent cancers with high unmet need and large markets Potential for

tissue-agnostic accelerated approval in virally- associated tumors Data from in-house analysis of TCGA database combined with other data sets; Confirmed in > 400 tumor microarrays The graph above reflects a logarithmic scale on each axis NPC

Nasopharyngeal; HNSCC Head & Neck Squamous Cell Carcinoma; NHL Non-Hodgkin Lymphoma; NSCLC Non-Small Cell Lung Cancer; TNBC Triple Negative Breast Cancer Treg CCR4 Ligands CD8 Signature Gastric EBV+ NPC EBV+ NSCLC Sq. TNBC Cervical HPV+ HNSCC

NSCLC Ad. Virally-Associated Non-Virally-Associated NHL

Phase 2: Gated Simon 2-Stage Design

FLX475 Monotherapy FLX475 w/ Pembrolizumab Nasopharyngeal (EBV+) Non-Small Cell Lung (CPI Experienced) Hodgkin/Non-Hodgkin Lymphoma (EBV+) Head & Neck (CPI Na ve) Cervical (HPV+) (CPI Na ve) TN Breast (CPI Na ve) Head & Neck

(CPI Na ve) Head & Neck (CPI Experienced) Stage 2 N=19 per cohort Stage 1 N=10 per cohort Endpoints: Safety, PK, Biomarkers, Tumor Response Assessment CPI = Checkpoint Inhibitor To evaluate the antitumor activity of FLX475 as monotherapy

and in combination with pembrolizumab in charged cancers that progressed after 1 line of therapy

Updated Stage 2 Decisions (September

2021) Nasopharyngeal (EBV+) Monotherapy Nasopharyngeal (EBV+) Monotherapy Nasopharyngeal (EBV+) Combination Go to Stage 2 Stop Stage 1 Stage 2 Decision EBV+ Lymphoma Monotherapy EBV+ Lymphoma Mono and Combo Stage 1 Pending NSCLC (CPI Experienced)

Combination Cervical (CPI Na ve) Monotherapy TN Breast (CPI Na ve) Combination Head & Neck (CPI Exp.) Combination Head & Neck (CPI Na ve) Monotherapy Head & Neck (CPI Na ve) Monotherapy Head & Neck (CPI

Na ve) Combination Head & Neck (CPI Exp.) Combination NSCLC (CPI Experienced) Combination TN Breast (CPI Na ve) Combination Head & Neck (CPI Na ve) Combination

FLX475 Phase 2 Program Summary

FLX475, a highly selective tumor Treg inhibitor, appears to be an active agent in charged cancers Demonstrated clinical activity as monotherapy Demonstrated clinical activity in combination with pembrolizumab in checkpoint-na ve cancers

beyond expected from checkpoint alone Ungated Stage 2 expansions in 4 indications EBV+ lymphoma, nasopharyngeal and head and neck cancers (CPI na ve and CPI refractory) Favorable safety supportive of broad combinability Targeting a medical

conference in 2022 for data presentation

Key Takeaways and Upcoming

Milestones RPT193: safe oral agent designed for an array of inflammatory diseases - Positive Phase 1b data in AD FLX475: a highly selective tumor Treg inhibitor in multiple Phase 2 expansions as monotherapy and in combination with

pembrolizumab Next Key Milestones Sept 2021: RPT193 late-breaking presentation at EADV Congress 2021 1H 2022: RPT193 Phase 2b AD trial initiation 2022: FLX475 Phase 2 data update 2022: RPT193 Phase 2a asthma trial initiation